MPP-Home

en / fr

Public health licensing to increase access and facilitate innovation: the Medicines Patent Pool model

Marie-Paule Kieny, Chair of the MPP Governance Board, gives an introduction of an article authored by Philippe Douste-Blazy; Charles Gore; Lelio Marmora; and herself, where they review the impact of the MPP and how its model can be adapted to other disease areas.

The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.

The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate

The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

Projections Tool

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

19 million patient-years through MPP’s generic partners from January 2012 to June 2018

24 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

150+

150+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

631

631 million dollars saved, from January 2012 to June 2018

Latest News

17 May 2019

G7 Health Ministers support expansion of the Medicines Patent Pool to essential medicines

Geneva, 17 May 2019 – In a joint declaration published today, the Health Ministers of Canada, France, Germany, Italy, Japan, the United Kingdom, the United States, and the European Commissioner for Health and Food Safety, gathered in Paris on 16-17 May, highlighted the importance of improving access to safe, effective, quality, affordable and essential health products and supported the expansion of the Medicines Patent Pool (MPP) to essential medicines. In 2018, at the request of the international community, the MPP expanded its mandate beyond treatment for HIV, hepatitis C and tuberculosis to other essential medicines. Last week, the MPP published its new framework for prioritising target medicines for in-licensing under its expanded mandate. “In 2011, the G8 had welcomed the establishment of the Unitaid-funded Patent Pool to facilitate the production of affordable HIV medicines well-adapted for use in resource-poor settings, encouraging the voluntary participation of patent holders” said Charles Gore,...

09 May 2019

The Medicines Patent Pool responds to call for feedback on the WHO draft Global Strategy for TB Research and Innovation

Geneva, 8 May 2019 – The Medicines Patent Pool (MPP) has provided feedback on the World Health Organization’s (WHO) draft Global Strategy for TB Research and Innovation. The foundation welcomes the fact that the Global Strategy acknowledges the critical importance of ensuring that people with tuberculosis (TB) can benefit from advancements in TB research and the need for new models of innovation that are not only needs driven and evidence based, but guided by the core principles of affordability, efficiency, equity, sustainability and collaboration. Patent pooling is recognised in the strategy as one possible approach to supporting the development of needed medicines in the context of an enabling environment for TB research and innovation. The MPP is the first patent pool in the field of health and as such welcomes the opportunity to offer its perspective on the potential of the approach in the field of TB. Read the MPP’s feedback in full HERE More information on the WHO call for contribution to the...

09 May 2019

The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate

The Medicines Patent Pool (MPP) has today published a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis. The framework considers a number of criteria, including the clinical importance of specific medicines, guided, where possible, by World Health Organization (WHO) existing assessments and aligned with established global health priorities. Also under consideration will be potential access challenges relating to these medicines and the potential for the MPP to address these challenges through its public health-oriented licensing and patent pooling model. The overall emphasis will be on ensuring greatest public health impact, especially in low- and middle-income countries. The publication of the framework follows an announcement in May 2018, that the MPP would expand its mandate following a recommendation from the World Health Organiza...

Videos

Unable to load video, please allow cookie

Endorsements

“I am honoured to be invited to represent the WHO on the MPP’s Governance Board. Access to essential medicines is fundamental to the ability of everyone to achieve the highest attainable standard of health and core to the Sustainable...”

Unable to load twitter timeline, please allow cookie